Abbott Laboratories $ABT Shares Bought by First Financial Bank Trust Division

First Financial Bank Trust Division lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 103,879 shares of the healthcare product maker’s stock after acquiring an additional 395 shares during the period. Abbott Laboratories accounts for approximately 1.2% of First Financial Bank Trust Division’s portfolio, making the stock its 19th biggest position. First Financial Bank Trust Division’s holdings in Abbott Laboratories were worth $14,129,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ABT. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $27,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $28,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $30,000. Wormser Freres Gestion purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $32,000. Finally, JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Mizuho boosted their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Stock Performance

NYSE ABT opened at $133.92 on Friday. The company has a market cap of $233.08 billion, a P/E ratio of 16.78, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock has a 50-day moving average of $130.41 and a two-hundred day moving average of $131.32. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.